www.aobiome.com Open in urlscan Pro
173.236.236.149  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Skip to content

AOBiome

 * Our Science
   * AOB and it’s impact on Inflammatory Conditions, and related Systemic
     Effects
   * Published Articles and Papers
 * Pipeline
 * Press
   * Company News
   * Press Releases
   * Conferences and Events
 * About Us
   * Leadership
   * Board
   * Investors
   * Contact Us




LIVE TOPICAL BIOTHERAPEUTICS FOR THE TREATMENT OF INFLAMMATORY SKIN DISORDERS

Learn More
•


LIVE TOPICAL BIOTHERAPEUTICS FOR THE TREATMENT OF INFLAMMATORY SKIN DISORDERS

Learn More


AN EVOLUTIONARY APPROACH TO RESTORING HEALTH

AOBiome Therapeutics is a late stage therapeutics company addressing a broad
range of inflammatory skin conditions by harnessing a single strain of class
defining Ammonia Oxidizing Bacteria (AOB), whose presence on the skin has been
eliminated through modern living.


RESTORING IMMUNE FUNCTIONALITY

Ammonia Oxidizing Bacteria may serve to restore proper immune response through
the down regulation of IL-4, IL-5, IL-13 and IL-31. Such markers are associated
with inappropriate inflammatory response in several diseases including the
pruritus (itch) pathway.


AOBIOME CURRENTLY HAS MULTIPLE
PHASE 2 CLINICAL PROGRAMS

AOBIOME CURRENTLY HAS PHASE 2 CLINICAL PROGRAMS IN ACNE, ECZEMA AND ROSACEA.

 

Learn More




COMMITTED TO TRANSFORMING & IMPROVING HUMAN HEALTH

We believe that the restoration of the symbiotic relationship between bacteria
and humans
will have a profound impact on human health.

Clinical Trials





Science





Manufacturing





Pipeline







 


Clinical Trials
Science
Manufacturing
About

In the News
May 16, 2023 · Cambridge, MA
AOBiome announces the publication of positive Phase 2b results in The Lancet’s
eClinicalMedicine for B244 in the treatment of mild-to-moderate atopic
dermatitis and moderate-to-severe pruritus
Read More
April 6, 2023 · Cambridge, MA
AOBiome Therapeutics Granted Composition of Matter Patent for its Clinical
Candidate B244
Read More
November 22, 2022 · Cambridge, MA
Todd Krueger, the President & CEO of AOBiome Therapeutics, Inc., featured in
Business Talk’s latest edition, “Top 10 Global Business Leaders Making a
Difference in 2022”
Read More
September 27, 2022 · Cambridge, MA
AOBiome Listed by The Silicon Review as one of the 50 Innovative companies to
watch in 2022
Read More


Read More



 * Our Science
   * AOB and it’s impact on Inflammatory Conditions, and related Systemic
     Effects
   * Published Articles and Papers
 * Pipeline
 * Press
   * Company News
   * Press Releases
   * Conferences and Events
 * About Us
   * Leadership
   * Board
   * Investors
   * Contact Us

© 2019 AOBiome | Terms & Conditions | Site Credits